Physician profile
James E Turner
NPI 1528083706
$314,154.56
in general payments reported to CMS, 2019-2025
30 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259K · 2020: $48K · 2021: $1,102 · 2022: $1,364 · 2023: $2,032 · 2024: $1,255 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,098 · Food and Beverage: $9.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,098.05 |
| Food and Beverage | $9.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $98,299.24 | 2019-2020 | |
| Celgene Corporation | $89,452.09 | 2019-2020 | |
| Amgen INC. | $50,136.92 | 2019-2020 | |
| Ucb, INC. | $28,275.41 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18,657.49 | 2019-2020 | |
| Abbvie INC. | $11,169.28 | 2019-2025 | |
| Janssen Biotech, INC. | $7,092.07 | 2019-2020 | |
| Lilly USA, LLC | $3,250.79 | 2019-2020 | |
| Allergan, INC. | $2,983.33 | 2019-2023 | |
| Helsinn Therapeutics (U.S.), INC. | $1,482.00 | 2020 | |
| Pfizer INC. | $538.80 | 2019-2020 | |
| Epi Health, LLC | $500.00 | 2019 | |
| Galderma Laboratories, L.P. | $368.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $368.03 | 2019-2020 | |
| Medimetriks Pharmaceuticals, INC. | $357.36 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $230.29 | 2019-2020 | |
| Genzyme Corporation | $221.51 | 2019-2020 | |
| Leo Pharma INC. | $176.45 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $128.26 | 2019-2020 | |
| Journey Medical Corporation | $127.32 | 2019 | |
| Melinta Therapeutics, LLC | $92.43 | 2019 | |
| Prugen, INC. Pharmaceuticals | $50.65 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $38.54 | 2019 | |
| Genentech USA, INC. | $35.87 | 2019 | |
| Dermira, INC. | $30.93 | 2019 | |
| Glaxosmithkline, LLC. | $30.00 | 2019 | |
| Encore Dermatology INC. | $24.01 | 2020 | |
| Mission Pharmacal Company | $12.69 | 2019 | |
| Sandoz INC. | $12.49 | 2019 | |
| Merck Sharp & Dohme LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.